Powered by

Lilly price break reverses NICE's 'No' ruling on breast cancer drug Verzenio

Jan 17, 2019 - FiercePharma

Last October, England's drug-cost watchdogs dealt Eli Lilly a blow when they decreedthat the company's CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn'tcost-effective. So Lilly dished up a new price breakā€”and now the National Institute for Health and Care Excellence (NICE)is on board.

The problem, initially, was that Lilly couldn't provide evidence that Verzenio (called Verzenios in Europe) is more effective than its two rivals, Pfizer's Ibrance and Novartis' Kisqali, for treati...